연구성과로 돌아가기

2024 연구성과별 연구자 정보 (1507 / 2344)

※ 현재 Web of Science 저자 정보만 집계되어 있습니다.
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
Document Title Author Full Name Author Short Name Index Corresponding Address ResearcherID ResearcherID Author Name ORCID ORCID Author Name Related Email
Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer: Updated Overall Survival Outcomes From Phase III PRODIGY Kim, Young-Woo Kim, YW 6 Natl Canc Ctr, Ctr Gastr Canc Res Inst & Hosp, Grad Sch Canc Sci & Policy, Goyang, South Korea ykkang@amc.seoul.kr;
Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer: Updated Overall Survival Outcomes From Phase III PRODIGY Kim, Jin Young Kim, JY 7 Keimyung Univ Dongsan Hosp, Dept Internal Med, Div Hemato Oncol, Daegu, South Korea JWP-3629-2024 Kim, Jin Il ykkang@amc.seoul.kr;
Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer: Updated Overall Survival Outcomes From Phase III PRODIGY Ryu, Min-Hee Ryu, MH 8 Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea 0000-0002-1033-1263 Ryu, Min-Hee ykkang@amc.seoul.kr;
Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer: Updated Overall Survival Outcomes From Phase III PRODIGY Rha, Sun Young Rha, SY 9 Yonsei Univ, Coll Med, Yonsei Canc Ctr, Dept Internal Med, Seoul, South Korea 0000-0002-2512-4531 Rha, Sun Young ykkang@amc.seoul.kr;
Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer: Updated Overall Survival Outcomes From Phase III PRODIGY Chung, Ik Joo Chung, IJ 10 Chonnam Natl Univ, Chonnam Natl Univ Hwasun Hosp, Dept Internal Med, Med Sch, Jeonnam, South Korea 0000-0003-0479-8067 Chung, Ik-Joo ykkang@amc.seoul.kr;
Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer: Updated Overall Survival Outcomes From Phase III PRODIGY Kim, In-Ho Kim, IH 11 Catholic Univ Korea, Seoul St Marys Hosp, Coll Med, Dept Internal Med,Div Med Oncol, Seoul, South Korea ykkang@amc.seoul.kr;
Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer: Updated Overall Survival Outcomes From Phase III PRODIGY Oh, Sang Cheul Oh, SC 12 Korea Univ Guro Hosp, Dept Internal Med, Seoul, South Korea ykkang@amc.seoul.kr;
Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer: Updated Overall Survival Outcomes From Phase III PRODIGY Park, Young Soo Park, YS 13 Univ Ulsan, Coll Med, Asan Med Ctr, Dept Pathol, Seoul, South Korea ykkang@amc.seoul.kr;
Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer: Updated Overall Survival Outcomes From Phase III PRODIGY Cheong, Jae-Ho Cheong, JH 14 Yonsei Univ Hlth Syst, Yonsei Canc Ctr, Dept Surg, Seoul, South Korea ykkang@amc.seoul.kr;
Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer: Updated Overall Survival Outcomes From Phase III PRODIGY Jeong, Oh Jeong, O 15 Chonnam Natl Univ, Dept Surg, Med Sch, Hwasun, South Korea ykkang@amc.seoul.kr;
Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer: Updated Overall Survival Outcomes From Phase III PRODIGY Heo, Mi Hwa Heo, MH 16 Keimyung Univ Dongsan Hosp, Dept Internal Med, Div Hemato Oncol, Daegu, South Korea ykkang@amc.seoul.kr;
Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer: Updated Overall Survival Outcomes From Phase III PRODIGY Kim, Hark Kyun Kim, HK 17 Natl Canc Ctr, Ctr Gastr Canc Res Inst & Hosp, Grad Sch Canc Sci & Policy, Goyang, South Korea ykkang@amc.seoul.kr;
Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer: Updated Overall Survival Outcomes From Phase III PRODIGY Park, Chohyun Park, C 18 Catholic Univ Korea, Seoul St Marys Hosp, Coll Med, Dept Surg, Seoul, South Korea ykkang@amc.seoul.kr;
Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer: Updated Overall Survival Outcomes From Phase III PRODIGY Yoo, Chang Hak Yoo, CH 19 Sungkyunkwan Univ, Kangbuk Samsung Hosp, Dept Surg, Sch Med, Seoul, South Korea ykkang@amc.seoul.kr;
Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer: Updated Overall Survival Outcomes From Phase III PRODIGY Kang, Seok Yun Kang, SY 20 Ajou Univ, Dept Hematol Oncol, Sch Med, Suwon, South Korea ykkang@amc.seoul.kr;
페이지 이동: